165 related articles for article (PubMed ID: 16761017)
1. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract][Full Text] [Related]
2. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
Brown P; Levis M; Shurtleff S; Campana D; Downing J; Small D
Blood; 2005 Jan; 105(2):812-20. PubMed ID: 15374878
[TBL] [Abstract][Full Text] [Related]
3. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
4. TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
Tamai M; Furuichi Y; Kasai S; Ando N; Harama D; Goi K; Inukai T; Kagami K; Abe M; Ichikawa H; Sugita K
Leuk Res; 2017 Oct; 61():68-76. PubMed ID: 28917156
[TBL] [Abstract][Full Text] [Related]
5. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
6. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
[TBL] [Abstract][Full Text] [Related]
7. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Schneider P; Nollau P; Horstmann M; Beverloo HB; van der Voort E; Valsecchi MG; de Lorenzo P; Sallan SE; Armstrong SA; Pieters R
Blood; 2005 Oct; 106(7):2484-90. PubMed ID: 15956279
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
9. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Brown PA; Kairalla JA; Hilden JM; Dreyer ZE; Carroll AJ; Heerema NA; Wang C; Devidas M; Gore L; Salzer WL; Winick NJ; Carroll WL; Raetz EA; Borowitz MJ; Small D; Loh ML; Hunger SP
Leukemia; 2021 May; 35(5):1279-1290. PubMed ID: 33623141
[TBL] [Abstract][Full Text] [Related]
10. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia.
Stam RW; den Boer ML; Schneider P; Meier M; Beverloo HB; Pieters R
Haematologica; 2007 Nov; 92(11):1565-8. PubMed ID: 18024407
[TBL] [Abstract][Full Text] [Related]
11. MLL-Rearranged Acute Lymphoblastic Leukemia.
El Chaer F; Keng M; Ballen KK
Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
[TBL] [Abstract][Full Text] [Related]
12. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.
Levis M; Pham R; Smith BD; Small D
Blood; 2004 Aug; 104(4):1145-50. PubMed ID: 15126317
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Schneider P; de Lorenzo P; Valsecchi MG; den Boer ML; Pieters R
Blood; 2007 Oct; 110(7):2774-5. PubMed ID: 17881645
[No Abstract] [Full Text] [Related]
14. The role of RAS mutations in MLL-rearranged leukaemia: A path to intervention?
Mansur MB; Ford AM; Emerenciano M
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):521-526. PubMed ID: 29056538
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K
Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100
[TBL] [Abstract][Full Text] [Related]
16. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
[TBL] [Abstract][Full Text] [Related]
18. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
[TBL] [Abstract][Full Text] [Related]
19. Relapsed infant MLL-rearranged acute lymphoblastic leukemia with additional genetic alterations.
Ishida H; Kanamitsu K; Washio K; Muraoka M; Sakakibara K; Matsubara T; Kanzaki H; Shimada A
Pediatr Blood Cancer; 2016 Nov; 63(11):2059-60. PubMed ID: 27322816
[No Abstract] [Full Text] [Related]
20. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
